Abstract

BackgroundValidity of European Scleroderma Study Group (EScSG) activity indexes currently used to assess disease activity in systemic sclerosis (SSc) has been criticised.MethodsThree investigators assigned an activity score on a 0–10...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0223 ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS: THE COMPARISON BETWEEN REVISED EUSTAR AND ESCSG ACTIVITY INDEXES
Murat Karabacak ... Sema Kaymaz Tahra
-
Murat Karabacak, et. al.Murat Karabacak ... Sema Kaymaz Tahra
27 May 2019
Performance of the 2017 EUSTAR activity index in an scleroderma cohort
Laura Ross ... Wendy Stevens
Clinical Rheumatology | VOL. 39
Laura Ross, et. al.Laura Ross ... Wendy Stevens
21 Jul 2020
Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis.
Ufuk İlgen ... Emine Gözde Aydemir Gülöksüz
Clinical rheumatology | VOL. 39
Ufuk İlgen, et. al.Ufuk İlgen ... Emine Gözde Aydemir Gülöksüz
18 Jul 2019
AB0823 A BAYESIAN APPROACH TO DETERMINE THE ROLE OF ORAL ANTICOAGULANTS FOR THE OCCURRENCE OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS – A EUSTAR OBSERVATIONAL STUDY
...
Annals of the Rheumatic Diseases | VOL. 82
, et. al. ...
30 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers